Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors-Reference-Cited by-同舟云学术

Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors

Published:2023-06-19 Issue:13 Volume:66 Page:8858-8875
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hu Shihe¹^ORCID,Liu Yu¹,Ma Jiye¹,Ding Weijie¹,Chen Hua¹,Jiang Haifang¹,Chen Hongxing¹,Wei Song¹,Liu Yonggao¹,Jin Qiaomei²³^ORCID,Yuan Haoliang⁴^ORCID,Yan Libo¹

Affiliation:

1. SkyRun Pharma Co., Ltd., No. 9 Weidi Road, Nanjing 210046, P. R. China

2. Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, P. R. China

3. Laboratories of Translational Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, Jiangsu, P. R. China

4. Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P. R. China

Funder

Nanjing University of Chinese Medicine

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00455

Reference47 articles.

1. AASLD guidelines for the treatment of hepatocellular carcinoma

2. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells

3. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

4. Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment

5. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and development of quinazoline compounds as irreversible pan-fibroblast growth factor receptor inhibitors with potent antitumor activities;Journal of Molecular Structure;2024-03

2. Discovery of potent and selective c-Met inhibitors for MET-amplified hepatocellular carcinoma treatment;European Journal of Medicinal Chemistry;2024-01